Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)Depreciation ExpenseEBIATLeasesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

Sunshine Biopharma (SBFM) Accumulated Depreciation & Amortization (2022 - 2025)

Sunshine Biopharma's Accumulated Depreciation & Amortization history spans 5 years, with the latest figure at $512879.0 for Q4 2025.

  • For Q4 2025, Accumulated Depreciation & Amortization rose 52.4% year-over-year to $512879.0; the TTM value through Dec 2025 reached $512879.0, up 52.4%, while the annual FY2025 figure was $512879.0, 52.4% up from the prior year.
  • Accumulated Depreciation & Amortization reached $512879.0 in Q4 2025 per SBFM's latest filing, up from $462469.0 in the prior quarter.
  • In the past five years, Accumulated Depreciation & Amortization ranged from a high of $512879.0 in Q4 2025 to a low of $83806.0 in Q4 2022.
  • Average Accumulated Depreciation & Amortization over 4 years is $338212.7, with a median of $369180.0 recorded in 2025.
  • Peak YoY movement for Accumulated Depreciation & Amortization: soared 126.71% in 2023, then surged 52.4% in 2025.
  • A 4-year view of Accumulated Depreciation & Amortization shows it stood at $83806.0 in 2022, then skyrocketed by 126.71% to $189996.0 in 2023, then soared by 77.13% to $336533.0 in 2024, then soared by 52.4% to $512879.0 in 2025.
  • Per Business Quant, the three most recent readings for SBFM's Accumulated Depreciation & Amortization are $512879.0 (Q4 2025), $462469.0 (Q3 2025), and $412626.0 (Q2 2025).